BridgeMD
Colchicine after Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial
EU CTIS ID: 2024-516033-12-00
What this study is testing
Documented atrial fibrillation recurrences within 6 months after ECV in patients with atrial fibrillation.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age >18 years
- Scheduled for ECV
- ECG-documented AF prior to ECV
- Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥1 hour after ECV
- Ability and provision of written informed consent
You likely can't join if
- AF persistence after cardioversion or early AF recurrence within 1 hour after ECV
- Any absolute indication for Colchicine intake
- Intake of a strong inhibitor of CYP3A4 or P-Glycoprotein
- Serious gastrointestinal disease
- Clinically overt hepatic disease
- Severe renal disease
See the full eligibility criteria
- Age >18 years
- Scheduled for ECV
- ECG-documented AF prior to ECV
- Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥1 hour after ECV
- Ability and provision of written informed consent
- AF persistence after cardioversion or early AF recurrence within 1 hour after ECV
- Any absolute indication for Colchicine intake
- Intake of a strong inhibitor of CYP3A4 or P-Glycoprotein
- Serious gastrointestinal disease
- Clinically overt hepatic disease
- Severe renal disease
- Men actively attempting to father children
- Any other contraindication for Colchicine intake
- Galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
- Clinically significant blood dyscrasia
- Significant immunosuppression
- Pregnant or breastfeeding womenwomen, or women of child-bearing potential who do not use a highly effective form of birth control during and 3 months following Colchicine treatment
- Life expectancy <1 year
- Prior enrolment in the COLECTRO-AF trial
- Any other rhythm than AF prior to ECV
- Pulmonary vein isolation within 3 months prior to ECV or pulmonary vein isolation planned in the next 3 months
- Known intolerance or hypersensitivity to Colchicine
The study team makes the final eligibility decision.
Where it's taking place
- Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.